MAP2K7 and neoplasm: By inhibiting MEK activity, selumetinib disrupts downstream signaling, thereby inhibiting tumor growth and proliferation. Selumetinib is approved for symptomatic plexiform neurofibromas that are not amenable to surgical resection in patients with NF1.